EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSCLAG00000002604
Gene Symbol: BTK
2 Cross references
206 Possible Orthologues:

C-C Chemokine Receptor Type 1

Ensembl ID : ENSCLAG00000017981
Gene Symbol: LOC102029518
1 Cross references
157 Possible Orthologues:

C-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSCLAG00000017900
Gene Symbol: LOC102029866
1 Cross references
157 Possible Orthologues:

C-C Chemokine Receptor Type 5

Ensembl ID : ENSCLAG00000014465
Gene Symbol: LOC102027648
1 Cross references
148 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSCLAG00000016011
Gene Symbol: CCR2
1 Cross references
148 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSCLAG00000004615
Gene Symbol: CCR4
3 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCLAG00000016177
Gene Symbol: CCR9
2 Cross references
265 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSCLAG00000004594
Gene Symbol: CXCL8
2 Cross references
179 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSCLAG00000018091
Gene Symbol: CXCR1
2 Cross references
230 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSCLAG00000017805
Gene Symbol: CXCR2
2 Cross references
238 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCLAG00000002279
Gene Symbol: CXCR4
2 Cross references
218 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCLAG00000003484
Gene Symbol: CFTR
2 Cross references
217 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).